BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employ
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.